OTC Medicines
Over-the-counter (OTC) or non-prescription medicines available to consumers without a prescription, subject to classification, safety monitoring, labeling, and pharmacist-guidance requirements.
Foresight tracks OTC Medicines developments and surfaces the alerts most likely to matter before they turn into missed deadlines, recalls, or escalation work.
Current activity
Steady
In line with the prior 8-week baseline
3-month trend
Latest alerts below
Last updated
2 April 2026, 17:37
Latest OTC Medicines alerts
The most recent regulatory and guidance signals tracked by Foresight
US FDA Publishes Lists of Companies That Did Not Submit 2024 Drug Amount Reports
The US FDA has publicly listed drug registrants that failed to submit mandatory 2024 annual drug amount reports, highlighting a breach of federal reporting requirements. Impacted companies face immediate reputational risk and must rectify listing inaccuracies to avoid further enforcement action and ensure continued market access.
United StatesUS House Introduces HERO Act (H.R. 7994) on Opioid Overdose Reversal Drugs in Schools
The US House introduced the HERO Act in March 2026 to fund opioid overdose reversal drugs and emergency response planning in schools. Educational institutions and pharmaceutical suppliers should prepare for increased demand and new mandatory reporting obligations to national overdose surveillance systems.
United StatesBrazil (ANVISA) Prohibits Irregular Dermatological Medicines and Esthetic Products Sold Online
ANVISA has prohibited the sale and use of irregular dermatological medicines and unregistered aesthetic medical devices marketed through online platforms in Brazil. This enforcement action underscores heightened regulatory scrutiny of e-commerce supply chains and the critical necessity for valid sanitary registrations for all healthcare and aesthetic products.
BrazilAustralia TGA Opens Consultation On Improving Sunscreen Regulation
Australia’s TGA has launched a consultation to modernize sunscreen regulation, targeting SPF testing reliability, laboratory oversight, and ingredient standards. Manufacturers should prepare for stricter quality assurance requirements, updated GMP guidance, and harmonized labeling rules between therapeutic and cosmetic products.
AustraliaNetherlands Water Boards Ask CBG To Act On Environmentally Harmful Self-Care Medicines
Dutch water authorities are formally requesting the medicines regulator to restrict over-the-counter sales of environmentally harmful topical analgesics like diclofenac. This signals a shift toward integrating environmental impact into pharmaceutical market access, potentially leading to stricter labeling or prescription-only status for high-risk substances.
NetherlandsUS FDA Publishes FY 2025 Drug Quality Sampling And Testing Results
The US FDA has released its FY 2025 drug quality surveillance results, confirming high compliance rates across tested pharmaceuticals with only one specific dissolution failure identified. This update signals the FDA's continued reliance on risk-based post-market testing to drive enforcement and quality improvements, necessitating rigorous supply chain oversight for manufacturers and distributors.
United StatesEU Council Circulates Draft Directive on Union Code for Medicinal Products for Human Use (Repeal of Directives 2001/83/EC and 2009/35/EC)
The EU Council has advanced a proposal for a new Union Code for medicinal products, set to repeal and consolidate the existing regulatory framework for human medicines and coloring agents. This major legislative overhaul will redefine compliance obligations for market access and supply chain operations, necessitating a strategic review of product portfolios and authorization strategies.
European UnionNetherlands Council Of State Refers Food Supplement–Medicine And Online Review Questions To CJEU (ECLI:NL:RVS:2026:1651)
The Dutch Council of State has referred questions to the CJEU to clarify the legal boundary between food supplements and medicinal products, specifically focusing on whether online consumer reviews can trigger a reclassification. This case will determine if retailers can be held liable under pharmaceutical laws for user-generated content and whether products clearly defined as supplements can be legally treated as medicines based solely on digital presentation.
NetherlandsEuropean UnionBrazil Enacts Law Allowing Pharmacies And Drugstores In Supermarkets
Brazil enacted Law No. 15.357/2026 in March 2026, permitting pharmacies to operate within supermarket premises under strict sanitary and operational conditions. This shift expands market access and retail competition while imposing rigorous compliance requirements for physical segregation, pharmacist oversight, and controlled substance handling.
BrazilUS FDA Issues Drug Safety Communication on Accidental Ingestion of OTC Eye Drops and Nasal Sprays by Children
The FDA has re-issued a safety communication regarding life-threatening risks to children from accidental ingestion of OTC eye drops and nasal sprays containing tetrahydrozoline, oxymetazoline, or naphazoline. Manufacturers of these products should anticipate increased regulatory pressure for child-resistant packaging and enhanced warning labels to mitigate pediatric poisoning risks.
United StatesUS FDA Announces Cardinal Health Recall of Webcol Large Alcohol Prep Pads for Microbial Contamination
Cardinal Health initiated a voluntary consumer-level recall of Webcol Large Alcohol Prep Pads in March 2026 due to microbial contamination risks. This enforcement action underscores the necessity for rigorous quality control and rapid response protocols to manage supply chain contamination and associated clinical liability.
United States
Puerto Rico
JapanUS House Introduces H.R. 7980 To Expand FFDCA Drug Recall Authority
US House Bill H.R. 7980 proposes expanding the FDA's mandatory recall authority from controlled substances to cover all drug categories. If enacted, this would significantly broaden federal enforcement powers, increasing compliance risk and operational liability for all pharmaceutical manufacturers.
United StatesUS FDA Issues Draft Guidance On New Approach Methodologies In Drug Development
The US FDA has released draft guidance establishing a validation framework for using New Approach Methodologies (NAMs) as alternatives to animal testing in drug development and OTC monograph submissions. This move signals a strategic shift toward human-biology-based testing, offering a pathway to reduce animal data reliance provided that "fit-for-purpose" validation meets regulatory standards.
United StatesPhilippines FDA Consults On Content Of License To Operate (LTO) For Pharmaceutical Establishments
The Philippines FDA has proposed standardized License to Operate (LTO) templates for pharmaceutical establishments, with a consultation period closing April 24, 2026. This shift to a uniform format and mandatory re-issuance for operational changes requires firms to update internal compliance tracking to ensure uninterrupted market access.
PhilippinesUS FDA Sets FY 2026 Facility Fee Rates for OTC Monograph Drug Facilities
The US FDA has finalized FY 2026 facility fee rates for OTC monograph drug facilities, setting fees at $19,188 for manufacturers and $12,792 for contract manufacturing organizations. Companies must ensure payment by 1 June 2026 to maintain compliance and prepare for a structural shift to October due dates in subsequent fiscal years.
United StatesUSITC Seeks Public-Interest Comments on Complaint Concerning OTC Lidocaine Patches (DN 3894)
The USITC is soliciting public interest comments on a Section 337 complaint that could lead to an import ban on certain over-the-counter lidocaine patches. Stakeholders face significant market access risks and should evaluate supply chain resilience if exclusion orders are issued against the named international manufacturers.
United StatesBrazil Anvisa Updates Reference Medicines List (LMR) Via IN 428/2026
Brazil’s Anvisa updated the Reference Medicines List (LMR) via Normative Instruction 428/2026, effective March 6, 2026. Pharmaceutical firms must immediately align bioequivalence and comparability studies with the revised benchmarks to ensure compliance for new registrations and post-approval changes.
BrazilCzechia Notifies Draft Pharmacopoeia Monograph for Unguentum Whitfield
Czechia has proposed a new pharmacopoeia monograph for Unguentum Whitfield, setting specific composition and quality standards for this medicinal ointment. Manufacturers of topical pharmaceutical products must ensure compliance with these updated formulation, testing, and storage requirements to maintain market access in Czechia.
CzechiaEuropean UnionJapan MHLW Seeks Comments on OTC Switch for Tocopherol Nicotinate
Japan’s MHLW is consulting on the reclassification of tocopherol nicotinate from prescription to over-the-counter (OTC) status through April 2026. This potential "switch OTC" offers market expansion opportunities but necessitates proactive assessment of consumer safety profiles, labeling requirements, and risk-mitigation strategies.
JapanBrazil (Anvisa) Issues Pharmacovigilance Alert on Liver Damage Risk from Turmeric Medicines and Supplements
Brazil’s Anvisa has issued a safety alert and mandated label warnings for turmeric-based medicines and supplements following reports of liver toxicity. Manufacturers of concentrated botanical extracts face immediate risk communication requirements and potential market restrictions as regulators re-evaluate high-bioavailability formulations.
BrazilRelated topics
Not a newsletter. Not a feed.
Structured intelligence mapped to your business.
These are just a few of the most recent OTC Medicines alerts. Foresight tracks every jurisdiction, every day — and surfaces only what affects your portfolio, with full citations and evidence.
Book a demoFrequently asked questions
Everything you need to know about Foresight's regulatory intelligence platform
Still have questions? Get in touch with our team
Join 3,500+ professionals staying ahead
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at
